Naphthyridine Derivatives Targeting GABAA Alpha 5 Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autism spectrum disorder (ASD) lack selective, pathophysiology-based medications, with existing pharmacological options having modest efficacy and tolerability issues, and there is an unmet need for compounds that can effectively target the GABAA α5 receptor to modulate neuronal excitability and improve symptoms.
Innovation Solution
Development of compounds of formula (I) with high affinity and selectivity for the GABAA α5 receptor, acting as positive allosteric modulators to treat or prevent diseases related to the GABAA α5 receptor, including ASD, by modulating neuronal excitability and restoring inhibitory synaptic transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmacological options are used for treating autism spectrum disorder, then treatment can be provided, but efficacy is modest and tolerability issues occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for the GABAA α5 receptor subunit rather than non-selective GABAA receptor modulation. This subunit-specific targeting localizes the pharmacological effect to a particular receptor subtype, improving efficacy for ASD symptoms while reducing off-target effects that cause tolerability issues with existing non-selective treatments
Solution Approach 2:
The patent employs parameter changes by modifying molecular structure parameters of the compounds to achieve optimal binding affinity and selectivity for the GABAA α5 receptor. By adjusting structural parameters such as substituent groups on the naphthyridine and pyrido[3,4-c]pyridazine cores, the compounds achieve enhanced efficacy while maintaining favorable tolerability profiles
2Reliability
If current treatments are used for ASD, then some therapeutic effect is achieved, but there is lack of selective, pathophysiology-based medications
Solution Approach 1:
The compounds are designed with local quality through subunit-selective binding to GABAA α5 receptors. The molecular structure includes specific pharmacophoric elements that target the unique characteristics of the α5 subunit, providing pathophysiology-based selectivity that current non-selective treatments lack, while maintaining therapeutic effectiveness
3Reliability
If GABAA α5 receptor modulation is implemented, then neuronal excitability is reduced and cognitive function is enhanced, but compound selectivity and affinity must be optimized
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular structure parameters to optimize both selectivity and affinity for the GABAA α5 receptor. The compounds feature specific substituent patterns and molecular weights that fine-tune binding characteristics, achieving the precision needed for effective cognitive enhancement while maintaining high selectivity
Data Source
AI summary
The present invention provides compounds of formula (I) and/or salts thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 positive allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation and intermediates of the preparation process thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.